Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and ...

While New Orleans prepares for the excitement of the big game, it’s important to remember that sports injuries aren’t limited to the professionals. High school athletes, weekend warriors, and generall ...

US FDA has approved its first ever non-opioid painkiller called suzetrigine. Experts believe it will prevent addiction ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty big deal,” Gupta said. “As you just mentioned, it’s been since 1998 that ...

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

Fentanyl has emerged as the primary cause of illicit drug deaths in Canada and the United States, and its trafficking has ...

Federal lawmakers are trying once again to push for a study on the “overmedication” of veterans by Department of Veterans ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

Learn more about whether Alkermes plc or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.